Morgan Stanley has incorporated BUD APAC's 2025 results and 2026 guidance into its forecasts. The firm has lowered its profit estimates for the company for the current and next fiscal years by 12% and 14%, respectively. Morgan Stanley introduced an earnings per share forecast of 6 cents for BUD APAC for 2028. It maintained an "Overweight" rating on the stock and extended its valuation base to 2026, keeping the target price at HK$9.
Due to an increased proportion of at-home consumption channels in China, the firm has reduced its average selling price forecast for 2026-2027 by 2% to 3%. This adjustment led to a decrease in the gross margin forecast for 2026 and 2027 by 1.1 and 2 percentage points, respectively. Morgan Stanley also raised its forecast for the sales, general, and administrative expense ratio, reflecting investments related to the channel shift in China and commercial investments in eastern and western regions.